Vyant Bio : Presentation – January 2022

N a s d a q - V Y N T

H U M A N - P O W E R E D D R U G D I S C O V E R Y

January - 2022

S A F E H A R B O R

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.'s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic collaborations and transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," and "estimates") should also be considered to be forward-looking statements. Forward- looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio, Inc. disclaims any obligation to update these forward-looking statements.

Nasdaq: VYNT

2

DRUG DISCOVERY

Needs a Paradigm Shift

Defines a New Approach

Underperformance of Widely Used Models for Predicting Drug Efficacy and Safety

Late Introduction of Human Biology in the R&D Process Leads to High Failure and Cost

Deep Expertise and Global Presence in Drug

Discovery

Human Biology and Data Science Driven

Proprietary Discovery Engine

Focused on Efficiently Discovering Novel Therapeutics for Neurological Developmental and Degenerative Diseases

Nasdaq: VYNT

3

Therapeutic Pipeline

Our Therapeutic Assets					IND
		P R E C L I N I C A L		C L I N I C A L
PROGRAM	INDICATION	EARLY DISCOVERY	TARGET ID & VALIDATION	LEAD ID	LEAD OPTIMIZATION	PHASES 1, 2, 3
VYNT-0126	Rett Syndrome					Vyant Bio
					Partner: Atomwise
ORAI-xxxx	Rett Syndrome
VYNT-xxxx	CDKL5				Partner: Cyclica
VYNT-xxxx	Parkinson's Disease		Vyant Bio
Multiple programs		Vyant Bio
from early discovery	Multiple Indications

through pre-clinical

Nasdaq: VYNT

4

Disease Model Assets

Our Platform/Disease Model Assets

DISEASE MODELS	PLATFORMS	PLATFORM & ASSAY DEVELOPMENT	PHENOTYPIC SCREENING	TARGET IDENTIFICATION & VALIDATION	COMPOUND IDENTIFICATION &
VALIDATION

Undisclosed Partner	microBrain®
Models
Rett Syndrome	microBrain®
CDKL5 Deficiency	microBrain®
Disorder
Parkinson's Disease	Mid-Brain/Dopaminergic
Brain Organoid
Models Under	Complex Cortical
Development	Organoids

Each Organ

Platform

Disease 1
Disease 2	• Each microOrgan® platform can create hundreds of diseases
	• Each Disease Model can discover multiple therapeutics
Disease 3

Disease x

Nasdaq: VYNT

5